Current studies of targeted alpha-particle therapy for hematologic malignancies
10.3760/cma.j.cn321828-20230129-00017
- VernacularTitle:α粒子靶向治疗血液系统恶性肿瘤研究现况
- Author:
Kangqi LIU
1
;
Haizhong ZHOU
;
Ling JIANG
;
Jie WANG
;
Xiaolong LIU
Author Information
1. 江苏省苏北人民医院核医学科，扬州 225001
- Keywords:
Hematologic neoplasms;
Radiotherapy;
Alpha particles;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2023;43(12):757-760
- CountryChina
- Language:Chinese
-
Abstract:
Hematological malignancies are suitable diseases for radioimmunotherapy because of their high sensitivity to radiation and well-defined immunophenotypes. Beta emitters like 131I and 90Y have achieved some outcomes in radioimmunotherapy of hematological malignancies. Compared with beta particles, alpha particles have higher linear energy transfer, greater relative biological effects and shorter range, which give alpha particles the ability to kill tumor cells more effectively with less damage to normal tissue. This review summarizes the current studies of targeted alpha-particle therapy in hematological malignancies.
